Halozyme Therapeutics (NASDAQ:HALO) Receives Buy Rating from Benchmark

Benchmark reiterated their buy rating on shares of Halozyme Therapeutics (NASDAQ:HALO) in a research report sent to investors on Thursday,Benzinga reports. Benchmark currently has a $75.00 price objective on the biopharmaceutical company’s stock.

Other analysts also recently issued research reports about the company. Piper Sandler lifted their target price on Halozyme Therapeutics from $52.00 to $53.00 and gave the company a “neutral” rating in a research report on Friday, January 10th. JMP Securities boosted their price target on Halozyme Therapeutics from $72.00 to $73.00 and gave the stock a “market outperform” rating in a research report on Friday, November 1st. Wells Fargo & Company cut their price objective on Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating for the company in a report on Monday, January 13th. Finally, HC Wainwright boosted their target price on shares of Halozyme Therapeutics from $70.00 to $72.00 and gave the stock a “buy” rating in a report on Wednesday. Four investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat, Halozyme Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $62.78.

Halozyme Therapeutics Trading Down 0.6 %

NASDAQ:HALO opened at $57.44 on Thursday. The company has a market cap of $7.31 billion, a P/E ratio of 16.75, a price-to-earnings-growth ratio of 0.44 and a beta of 1.25. Halozyme Therapeutics has a twelve month low of $36.61 and a twelve month high of $65.53. The business has a 50 day moving average price of $53.26 and a two-hundred day moving average price of $54.58. The company has a quick ratio of 9.15, a current ratio of 10.36 and a debt-to-equity ratio of 3.32.

Halozyme Therapeutics (NASDAQ:HALO) last announced its earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 EPS for the quarter, topping the consensus estimate of $1.17 by $0.02. The business had revenue of $298.01 million during the quarter, compared to analysts’ expectations of $285.74 million. Halozyme Therapeutics had a net margin of 43.74% and a return on equity of 165.13%. As a group, analysts expect that Halozyme Therapeutics will post 4.72 EPS for the current fiscal year.

Insider Buying and Selling at Halozyme Therapeutics

In related news, Director Jeffrey William Henderson sold 5,000 shares of the company’s stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $56.30, for a total value of $281,500.00. Following the transaction, the director now owns 38,611 shares in the company, valued at approximately $2,173,799.30. This represents a 11.46 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 2.40% of the company’s stock.

Institutional Investors Weigh In On Halozyme Therapeutics

A number of institutional investors have recently made changes to their positions in HALO. Vanguard Group Inc. increased its stake in shares of Halozyme Therapeutics by 3.0% during the fourth quarter. Vanguard Group Inc. now owns 13,281,714 shares of the biopharmaceutical company’s stock worth $634,999,000 after purchasing an additional 386,618 shares during the period. Snyder Capital Management L P grew its holdings in Halozyme Therapeutics by 2.6% in the 4th quarter. Snyder Capital Management L P now owns 4,168,453 shares of the biopharmaceutical company’s stock valued at $199,294,000 after buying an additional 105,086 shares in the last quarter. Geode Capital Management LLC grew its holdings in Halozyme Therapeutics by 1.0% in the 3rd quarter. Geode Capital Management LLC now owns 3,060,131 shares of the biopharmaceutical company’s stock valued at $175,194,000 after buying an additional 30,901 shares in the last quarter. Congress Asset Management Co. increased its position in Halozyme Therapeutics by 446.5% during the 3rd quarter. Congress Asset Management Co. now owns 2,433,579 shares of the biopharmaceutical company’s stock worth $139,298,000 after buying an additional 1,988,238 shares during the period. Finally, Dimensional Fund Advisors LP lifted its holdings in shares of Halozyme Therapeutics by 2.5% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,933,560 shares of the biopharmaceutical company’s stock worth $92,446,000 after buying an additional 47,795 shares in the last quarter. Institutional investors own 97.79% of the company’s stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.